Company intelligence / Profile preview

Küleon

Seattle, Washington, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Küleon has developed the first known trifunctional serotonergic small molecule KB-128, which is a full agonist at 5-HT2C and a full antagonist at 5-HT2A and 5-HT2B. KB-128 has completed initial ADME/PK and toxicology studies with strong results and is advancing through IND-enabling studies. No clinical results yet released; company states high selectivity, low off-target activity, and promising pharmacokinetic properties.[2][4]

Therapeutic areas: ImmunologyNeurologyEndocrinologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

KB-128

Preclinical

Beyond the preview

Go deeper on Küleon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Küleon.

Explore the full profile